The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation (KONNECTION) |
|---|---|
| Study Drug | Ivacaftor (VX770) |
| Type of Study Drug | CFTR Modulation |
| Study Title | A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Crossover Study With an Open-Label Period to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation |
| Study Phase | 3 |
| Study Sponsor | Vertex |
https://clinicaltrials.gov/ct2/show/NCT02456103 (link is external) | |
| Participating ECFS-CTN sites | Belgium: Leuven France: Lyon, Montpellier, West-Paris (Debré) |
| Age | 6 Years and older |